Anixa Biosciences Inc (NASDAQ:ANIX) Sees Significant Increase in Short Interest

Anixa Biosciences Inc (NASDAQ:ANIX) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 795,400 shares, an increase of 40.7% from the November 30th total of 565,273 shares. Currently, 3.2% of the company’s stock are short sold. Based on an average daily trading volume, of 719,327 shares, the short-interest ratio is currently 1.1 days. Based on an average daily trading volume, of 719,327 shares, the short-interest ratio is currently 1.1 days. Currently, 3.2% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

ANIX has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a research report on Thursday, September 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Anixa Biosciences in a report on Monday, December 22nd. D. Boral Capital reiterated a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research note on Friday, December 12th. Zacks Research downgraded shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 18th. Finally, Wall Street Zen cut shares of Anixa Biosciences from a “hold” rating to a “sell” rating in a report on Saturday. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Anixa Biosciences currently has an average rating of “Hold” and an average target price of $9.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Anixa Biosciences by 2.1% in the third quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company’s stock worth $4,694,000 after acquiring an additional 29,436 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Anixa Biosciences by 1.7% during the third quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock valued at $706,000 after purchasing an additional 3,645 shares during the last quarter. Citadel Advisors LLC raised its position in shares of Anixa Biosciences by 31.6% during the 3rd quarter. Citadel Advisors LLC now owns 96,010 shares of the company’s stock worth $317,000 after purchasing an additional 23,072 shares during the period. Susquehanna International Group LLP raised its position in shares of Anixa Biosciences by 378.4% during the 3rd quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock worth $265,000 after purchasing an additional 63,584 shares during the period. Finally, Jane Street Group LLC lifted its holdings in shares of Anixa Biosciences by 37.2% in the 2nd quarter. Jane Street Group LLC now owns 41,800 shares of the company’s stock worth $138,000 after purchasing an additional 11,340 shares during the last quarter. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Trading Down 6.4%

Shares of ANIX opened at $3.20 on Monday. Anixa Biosciences has a 52 week low of $2.07 and a 52 week high of $5.46. The firm has a market cap of $105.34 million, a price-to-earnings ratio of -9.14 and a beta of 0.49. The stock has a 50 day moving average of $4.15 and a 200-day moving average of $3.62.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.